Dual-action weight loss.
In a daily tablet.
Luma's physician-compounded Oral Tirzepatide delivers the same dual GIP and GLP-1 receptor mechanism as the injection — in a simple daily pill. Up to 22% body weight reduction in clinical trials.*
Same mechanism.
Zero needles.
Oral Tirzepatide gives you the identical dual-receptor mechanism as the injectable version — reformulated into a once-daily tablet for patients who want powerful results without the needle.
- Once-weekly subcutaneous injection
- Avg. up to 22% body weight reduction
- Targets both GIP & GLP-1 receptors
- Requires needle & at-home administration
- $165/month all-inclusive
- Once-daily tablet — no injection
- Avg. up to 22% body weight reduction
- Targets both GIP & GLP-1 receptors
- Simply swallow with water each morning
- $100/month all-inclusive
How Oral Tirzepatide works.
Oral Tirzepatide activates both the GIP and GLP-1 receptors — the same dual-hormone pathway as the injectable version — through a compounded tablet formulated for oral absorption.
Dual Receptor Action
Oral Tirzepatide activates both GIP and GLP-1 receptors simultaneously — amplifying appetite suppression and metabolic benefits, just like the injectable formulation.
One Tablet, Once Daily
No vials, no needles, no sharps disposal. Just one tablet each morning with water — easy to take on the go, at work, or while traveling.
Crushes Cravings
The combined hormonal effect delivers stronger, more sustained appetite suppression than GLP-1 alone — making it significantly easier to maintain a calorie deficit without feeling deprived.
What to expect.
Oral Tirzepatide is safe and well-tolerated by most patients. Side effects are typically mild and improve as your body adjusts to the medication.
🟡 Common Side Effects
- Nausea (most common, especially early)
- Reduced appetite
- Mild constipation or diarrhea
- Headache during dose adjustment
- Mild fatigue in first few weeks
✅ You're Supported
- Same-day provider visits
- 24/7 care team messaging
- Dose adjusted to your body's response
- FSA & HSA eligible
- Payment plans via Affirm available
No — Luma's compounded Oral Tirzepatide is not a brand-name drug. It is a physician-compounded dual GIP and GLP-1 receptor agonist containing Tirzepatide, prepared as a tablet by a licensed compounding pharmacy based on your provider's prescription. Compounded medications are not FDA-approved brand-name products, but offer the same clinically studied active molecule at a significantly lower cost.
Both formulations activate the same two hormone receptors — GIP and GLP-1 — for the same dual-action mechanism. The oral version is compounded into a daily tablet instead of a weekly injection, so there's no needle, no vial, and no at-home administration required.
Oral Tirzepatide is taken as one tablet by mouth, typically once daily with water. Full dosing instructions are included with every shipment, and your care team will guide you through any dose adjustments.
Most patients notice significantly reduced appetite within the first 1–2 weeks. Visible weight loss typically begins by weeks 4–8. The most dramatic results occur between months 3–6 as your dose reaches its therapeutic level.
Yes to both. Luma Health treatments are FSA and HSA eligible. We also accept Affirm — split your costs into simple monthly payments with no hidden fees, approved in seconds at checkout.
Ready for results
without the needle?
Complete a short health assessment and meet with a licensed provider — same day visits available.